Adalat ® XL® vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients

Condition(s) targeted: Diabetic Nephropathies; Hypertension

Intervention: Adalat® XL® (Drug); Tiazac® XC (Drug)

Phase: Phase 3

Status: Not yet recruiting

Sponsored by: Bayer

Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer

Overall contact:
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com

The study consists of a 12 week run-in period when all subjects are stabilized on a single dose of Avalide® (300 mg/12. 5 mg or 300mg/25mg dose) per day. After this 12 week run-in ends, subjects will be randomly assigned to start the addition of either Adalat® XL® or Tiazac® XC for 18 weeks of treatment. Subjects will have a 1 in 2 chance of receiving the study drug Adalat®XL® and a 1 in 2 chance of receiving the drug Tiazac® XC. An end of treatment visit will be done 18 weeks after start of study drug. The expected duration of the study is 30 weeks. The purpose of this study is to compare the change in proteinuria, through a urine test, while taking study drug until high blood pressure (BP) is reduced to near normal levels in study subjects with diabetic nephropathy and hypertension.

Official title: Randomized Open-Label 2-Arm Parallel Design Comparator Study of the Effect of Adalat® XL® Compared to Diltiazem on Proteinuria and Blood Pressure in Patients With Diabetes and Mild to Moderate Hypertension When Used as an Add on to Avalide®

Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: Change in Proteinuria

Secondary outcome:

Percentage of subjects reaching a BP target of 130/80 mmHg at Week 18

Number and doses of anti-hypertensives used in the 2 treatment arms

Levels of urinary albumin and protein content and estimated glomerular filtration rate (GFR) in the 2 treatment groups

Early BP reduction from randomization achieved with the starting dose in the 2 treatment arms

Adverse Events leading to early withdrawal

All Adverse Events especially, edema

Change in index of glycemia (HbA1c)

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- ≥18 and < 80 years old.

- Diagnosed with hypertension.

- Diagnosed with diabetes mellitus type 2 for at least 6 mths prior to entry and on

stable medication for diabetes for at 1 mth prior to screening.

- Treated on ARB, ACE inhibitor with or without hydrochlorothiazide and suitable to

receive combination therapy with Avalide at 300mg/12. 5mg per day or 300mg/25mg per day.

- Diagnosed with diabetic nephropathy and have proteinuria between 0. 8g/day and 5. 0g/day

at screening and then between 0. 8g/day and 3. 0g/day at randomization.

- Medically appropriate to receive Adalat XL or Tiazac XC.

Exclusion Criteria:

- History of alcohol or substance abuse.

- Significant CV disorder such as ischemic heart disease, arrhythmias within the last 6

mths, or any history of severe congestive heart failure.

- Myocarditis or pericarditis within last 30 day of screening.

- ECG showing evidence of major arrhythmia or conduction disturbances requiring

treatment with anti-arrhythmic medication.

- Females with child-bearing potential or males with a partner of child-bearing

potential unless willing to use effective contraception during the study and 3 mths after the end of study.

- Females who are pregnant, lactating or planning pregnancy during the study and for 3

mths after the study end.

- Known hypersensitivity to Adalat XL or Tiazac XC or other calcium channel blockers of

the dihydropyridine class.

- Resting heart rate <50 or >110 bpm.

- Presence of secondary or malignant hypertension.

- DBP≥180 and/or SBP≥110 mmHg.

Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com

Quebec G1R 2J6, Canada

Calgary, Alberta T2N 4N1, Canada

Edmonton, Alberta T6G 2B7, Canada

Vancouver, British Columbia V6Z 1Y6, Canada

Vancouver, British Columbia V6H 2Z6, Canada

Winnipeg, Manitoba R3A 1R9, Canada

Sydney, Nova Scotia B1P 1P3, Canada

Oshawa, Ontario L1H 1B9, Canada

London, Ontario N6A 5A5, Canada

Kitchener, Ontario N2H 5Z8, Canada

Toronto, Ontario M5C 2T2, Canada

Courtice, Ontario L1E 3C3, Canada

Toronto, Ontario M4N 3M5, Canada

Thunder Bay, Ontario P7E 6E7, Canada

Toronto, Ontario M4C 5T2, Canada

Ottawa, Ontario K1H 7W9, Canada

Toronto, Ontario M3N 1N1, Canada

Montreal, Quebec H2W 1T8, Canada

Montreal, Quebec H1T 2M4, Canada

Greenfield Park, Quebec J4V 2H1, Canada

Saskatoon, Saskatchewan S7M 2Z1, Canada

Click here to find results for studies related to marketed products

Click here and search for drug information provided by the FDA

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product

Starting date: September 2008
Ending date: December 2009
Last updated: September 2, 2008